RESULTS	The composite of the safety and efficacy endpoints at 9 days ( 10.0 % vs. 16.0 % , HR 0.61 , 95 % CI 0.31-1 .10 , P = 0.10 ) , 30 days ( 14.0 % vs. 17.9 % , HR 0.72 , 95 % CI 0.47-1 .16 , P = 0.21 ) , or 180 days ( 18.7 % vs. 27.3 % , HR 0.65 , 95 % CI 0.38-1 .11 , P = 0.11 ) showed a non-significant trend toward a lower value in group F.\